-
-
-
-
-
-
-
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
-
-
-
-
-
-
-
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
-
-
-
-
-
-
-
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
-
-
-
-
-
-
-
22nd Century Group (XXII) Announces CFO Transition
-
-
-
-
-
-
-
Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

